Brafman told the judge that Shkreli is still considering whether to use a "reliance-of-counsel" defense, in which he might seek to blame Greebel for his actions.
The brash former executive, known to lash out at journalists and critics on Twitter, was arrested in December and accused of defrauding investors in hedge funds he ran and using $11 million in Retrophin assets to pay them off.
In a new indictment filed Friday, he is also accused of secretly hiding his control of unrestricted stock in the company, which prosecutors allege he used to help satisfy his debts.
While CEO of Turing Pharmaceuticals, Shkreli rose to infamy last year when the company raised the price of a rare treatment for a potentially deadly infection by more than 5,000 percent.
Although the criminal case has nothing to do with the price increase, Shkreli has said he was targeted by prosecutors because of his notoriety.
Speaking outside the courthouse following a short hearing, Brafman told reporters that he doesn't think the new charge "adds anything of value" to the government's case.
Shkreli and Greebel are scheduled to appear in court again on July 14.
- Bloomberg